ISL
10.9.2019 15:21:12 CEST | Business Wire | Press release
Australian stars Kyle Chalmers, Cate and Bronte Campbell, Ariarne Titmus and Mitch Larkin will compete in a new professional league pitting the world’s best swimmers against each other in a revolutionary club-based competition, which will be shown exclusively live in Australia on 7plus.
The International Swimming League (ISL) will hold its inaugural meet in Indianapolis next month, when eight teams – four from the United States and four from Europe – will compete over two days in a full program of events over 50m to 400m.
This will be the first of seven ISL meets across the United States and Europe in 2019, with the top four teams qualifying for the final in Las Vegas in December.
With more than $5 million in prize money at stake, and most of swimming’s current Olympic champions and world-record holders set to take part, the competition will be fierce and is bound to showcase many of the captivating rivalries expected to take centre stage at the Olympic Games Tokyo 2020.
The international big names competing include Titmus’ great rival Katie Ledecky and fellow giants of the pool Adam Peaty, Sarah Sjostrom, Ryan Murphy, Federica Pellegrini, Chad le Clos and Nathan Adrian.
The Aussie contingent taking part also includes Emma McKeon, Cam McEvoy, Emily Seebohm, Clyde Lewis, Jess Hansen and Holly Barratt, giving swimming fans a chance like never before to track the progress of our brightest Olympic Games medal hopes as Tokyo 2020 draws ever closer.
Seven’s Head of Sport Saul Shtein said: “The ISL will give swimming an established place in the annual sporting calendar and offers sports fans the chance to watch the world’s best compete regularly in an exciting new format, while this inaugural season should also provide a tantalising lead-in to Tokyo 2020. We’re thrilled to bring it to our viewers and to be adding more premium live content to 7plus.”
Kontantin Grigorishin, ISL President, declared: "We are very excited about this partnership with Seven Sport, which will allow millions of fans in Australia to experience full live coverage of International Swimming League. The heart of swimming beats in Australia and will beat even stronger from October 6 with the first ever match of ISL in Indianapolis."
Swimming fans will also be able to watch highlights of every ISL meet on 7TWO and 7plus.
In 2020, Seven is the home of the Australian swimming Olympic Games trials and Tokyo 2020.
TV Broadcast times: October 6-7 ISL – Group A: Match 1 Indianapolis, USA Sydney 5.00am LIVE on 7plus Melbourne 5.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 4.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 13-14 ISL – Group A: Match 2 Naples, Italy Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
October 20-21 ISL – Group B: Match 1 Dallas, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
October 27-28 ISL – Group B: Match 2 Budapest, Hungary Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
November 17-18 ISL – USA Derby Washington DC, USA Sydney 6.00am LIVE on 7plus Melbourne 6.00am LIVE on 7plus Brisbane 5.00am LIVE on 7plus Adelaide 5.30am LIVE on 7plus Perth 3.00am LIVE on 7plus
November 24-25 ISL – Europe Derby London, UK Sydney 4.00am LIVE on 7plus Melbourne 4.00am LIVE on 7plus Brisbane 3.00am LIVE on 7plus Adelaide 3.30am LIVE on 7plus Perth 1.00am LIVE on 7plus
December 21-22 ISL – Final Las Vegas, USA TBC
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005683/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom